Pre-ClinicalHTS & Lead DiscoveryPhase 1Phase 2Phase 3LaunchTarget Validation
Our service expertise spans the drug discovery process.
Screening and ProflingServices
Biochemical and cell-basedunctional assays or kinase, GPCR,ion channel and ubiquitinationtargets ● Proling services ●Customized solutions throughassay development.
Industry-leading, unctionalproling against 125 GPCR, kinase,phosphatase and ion channel targets.
Cell-Based Assay Services
GPCRProler® and IonChannelProler™ services integrate EMD Millipore’s stable GPCR and ion channel cell line products into unctional assays or small and large moleculepotency and selectivity proling ● GxP-compliant services or testing neutralizing antibody assays during tiered immunogenicity testing and in potency and stability testingo biotherapeutics.
Biomarker Analysis Services
Protein and nucleic acid biomarker analysis ● RIA, ELISA, Luminex® xMAP® technology, electrochemiluminescence (ECL), Gyrolab® and fow cytometry services using the EMD Millipore portolio o assays or commerciallyavailable kits rom any vendor ● Transer, develop and validate custom assays to meet your requirements ● Exploratory and GxP nucleic acid analysis using the latest qPCR and Pyrosequencing® instrumentation.
Biopharmaceutical Analysis Services
Experienced development and perormance o cell-based potency and ligand binding assays or impurity testing, batchrelease and testing o stability samples ● Claim compliance to GMP or regulatory submission or as a non-regulatory studyunder the same high quality standards ● Wide range o cell-based assays (e.g. ADCC, cell prolieration, receptor binding)and ligand binding techniques including ELISA/RIA, Luminex® xMAP® Technology, surace plasmon resonance (Biacore™), ECLand immunoblotting.
Industry-leading experience in the development and validation o PK/TK assays or the measurement o large moleculesand peptides ● Scalable solutions to meet your specic needs, rom routine sample analysis through to ull-service assaydevelopment and validation.
Adhering to current FDA and EMA guidelines and AAPS white papers, we ollow a stepwise approach to measure anti-drugantibody responses using ELISA/RIA, surace plasmon resonance, GyroLab®, ECL, DELFIA® and Nab analysis using cell-basedassays ● We transer, develop and validate methods and evaluate several platorms to ensure optimal data quality ● Withunsurpassed industry experience, EMD Millipore provides the technical expertise, quality assurance and peace o mindthat are essential when considering a partner or research, preclinical through to clinical regulated assay development andsample analysis on any scale.
From discovery throughdevelopment.